摘要
Background: Camrelizumab plus apatinib shows encouraging antitumor activity and acceptable toxicity in chemotherapy-pretreated patients with advanced non-small cell lung cancer (NSCLC), however, clinical benefits from this combination regimen in NSCLC patients with EGFR mutations or ALK rearrangements (EGFR+/ALK+) have not been reported. We assessed the efficacy and safety of this combined regimen in pretreated patients with advanced NSCLC and defined EGFR/ALK status (EGFR+/ ALK+) in a phase lb/2 trial. @@@ Methods: Previously treated patients with advanced EGFR+/ALK+ NSCLC were enrolled and given camrelizumab 200 mg intravenously every 2 weeks plus apatinib at the recommended dose of 250 mg orally once daily. Patients harboring sensitive EGFR mutations or ALK fusion genes had received at least one EGFR/ALK TKI and a platinum-based chemotherapy regimen before the enrollment. The primary endpoint was objective response rate (ORR). @@@ Results: All 43 enrolled patients comprised the efficacy and safety analysis population. The confirmed ORR was 18.6% (95% CI: 8.4-33.4) and the dinical benefit response rate was 27.9% (95% CI: 15.3-43.7). Median progression-free survival (PFS) was 2.8 months (95% CI: 1.9-5.5) and median overall survival was not reached (95% CI: 7.3-not reached), with a median follow-up period of 15.7 months (range, 0.5-24.4). The most common grade >= 3 treatment-related adverse events (TRAEs) were hypertension (16.3%), proteinuria (11.6%) and palmar-plantar erythrodysaesthesia syndrome (9.3%). No unexpected adverse events were recorded. @@@ Conclusions: Camrelizumab plus apatinib showed moderate antitumor activity and acceptable safety profile in previously treated patients with advanced NSCLC and EGFR or ALK genetic aberrations, which warranted further validation.
学科与关键词
- Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancerGao, Guanghui; Zhao, Jun; Ren, Shengxiang; Wang, Yina; Chen, Gongyan; Chen, Jianhua; Gu, Kangsheng; Guo, Renhua; Pan, Yueyin; Wang, Quanren; Li, Weixia; Yang, Xinfeng; Zhou, Caicun*Annals of Translational Medicine, 2022, 10(8): 441.被引 11
- Effectiveness and safety of camrelizumab in inoperable or advanced non-small cell lung cancer patients: a multicenter real- world retrospective observational study (CTONG2004-ADV)Xu, Chong-Rui; Chen, Qixun; Zhou, Chengzhi; Wu, Lin; Li, Wen; Zhang, Huizhong; Li, Yongsheng; Xu, Fei; Xiong, Jianping; Wang, Qiming; Zhang, Haibo; Jiang, Yuequan; Yin, Haitao; Wu, Qingchen; Dai, Qiangsheng; Hu, Jian; Chen, Jianhua; Zhang, Jian; Wu, Gang; Yin, Jun; Zhao, Jianfu; Liu, Baogang; Shan, Jianzhen; Sheng, Liming; Chen, Qunqing; Han, Zhengxiang; Shi, Huaqiu; Liu, Yimin; Chen, Jun; Wu, Yi-Long*Translational Lung Cancer Research, 2023, 12(1): 127-+.
- First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trialRen, Shengxiang; Wang, Xicheng; Han, Bao-Hui; Pan, Yueyin; Zhao, Jun; Cheng, Yufeng; Hu, Sheng; Liu, Tianshu; Li, Yalun; Cheng, Ying; Feng, Jifeng; Yi, Shanyong; Gu, Shanzhi; Gao, Shegan; Luo, Yongzhong; Liu, Ying; Liu, Caigang; Duan, Huijie; Wang, Shuni; Yang, Xinfeng; Fan, Jia*; Zhou, Caicun*Journal for ImmunoTherapy of Cancer, 2024, 12(2): e007227.
